| ns0:DescribedValueSet  
|   : ID^2.16.840.1.113883.3.526.3.1317
|   : displayName^Allergy to Tamoxifen or Aromatase Inhibitor Therapy
|   : version^20121025
|  | ns0:ConceptList  
                Code    System         Description
           293790002  SNOMEDCT  Tamoxifen allergy (disorder)
|  | ns0:Source American Medical Association-convened Physician Consortium for Performance Improvement(R)
|  | ns0:Definition (2.16.840.1.113883.3.526.2.1383:Allergy to Tamoxifen or Aromatase Inhibitor Therapy)
|  | ns0:Type Grouping
|  | ns0:Binding Dynamic
|  | ns0:Status Active
|  | ns0:RevisionDate 2012-07-30
--------------------------------------------------------------
CATEGORY: Condition/Diagnosis/Problem
CMS eMeasure ID: CMS140v1
Endorsed By: National Quality Forum
GUID: ac639794-cb3f-4f4f-8fa6-680300d5ed4e
Meaningful Use Measures: CY 2014 EP
Measure Developer: American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
Measure Steward: American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
Measure Type: PROCESS
NQF Number: 0387
SHEETNAME: Onc_Breast_Cancer
eMeasure Copyright: Copyright 2012 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.
eMeasure Description: Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period
eMeasure Identifier: 140
eMeasure Status: Complete
eMeasure Title: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
eMeasure Version number: 1
